COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
An estimated 2.8% of Indiana residents aged 12 or older randomly tested in late April had SARS-CoV-2 infection or antibodies, and 44% of those with active infections reported no symptoms, according to a July 21 report released by the Centers for Disease Control and Prevention.
The Food and Drug Administration last week reissued its emergency use authorization of Quest Diagnostics鈥 SARS-CoV-2 rRT-PCR test for use with pooled samples containing up to four individual swab specimens collected under observation.
The New England Journal of Medicine last week released a study showing that the use of dexamethasone resulted in a lower, 28-day mortality rate among patients receiving invasive ventilation or oxygen.
The Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response July 21 at 12 p.m. ET will host a COVID-19 webinar on 鈥淐ritical Care: Lifesaving Treatment and Clinical Operations.鈥
The Food and Drug Administration at 8 p.m. will close its COVID-19 hotline for questions related to COVID-19 diagnostic tests and device shortages, including personal protective equipment and respirators.
The Centers for Disease Control and Prevention is developing guidance that will no longer recommend a second negative test within 24 hours before COVID-19 patients emerge from isolation, according to news reports from a press call with Brett Giroir, M.D., assistant secretary for health at the鈥
The Food and Drug Administration added to its FAQs on testing for SARS-CoV-2 a list of laboratories that should no longer be used.
The Food and Drug Administration added dexamethasone sodium phosphate to its lists for temporary compounding by outsourcing facilities and pharmacy compounders during the COVID-19 emergency.
Two new case studies affirm that cloth face coverings 鈥渁re a critical tool in the fight against COVID-19 that could reduce the spread of the disease, particularly when used universally within communities,鈥 the Centers for Disease Control and Prevention said.
The Food and Drug Administration authorized emergency use for a non-invasive nerve stimulator at home or in health care settings to treat suspected COVID-19 patients experiencing worsened asthma-related shortness of breath and reduced airflow.